Archeus Technologies and Wisconsin Alumni Research Foundation to Advance ART-101 into Clinical Development for Prostate Cancer
“With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,” said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. “Leveraging our team’s proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo